The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Spiroindolone KAE609 for Falciparum and Vivax Malaria
Open accessAbstract
BACKGROUND: KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analogue with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum. METHODS: We conducted a phase 2, open-label study at three centers in Thailand to assess the antimalarial efficacy, safety, and adverse-event profile of KAE609, at a dose of 30 mg per day for 3 days, in two sequential cohorts of adults with uncomplicated P. vivax malaria (10 patients) or P. falciparum malaria (11). The primary end point was the parasite clearance time. RESULTS: The median parasite clearance time was 12 hours in each cohort (interquartile range, 8 to 16 hours in patients with P. vivax malaria and 10 to 16 hours in those with P. falciparum malaria). The median half-lives for parasite clearance were 0.95 hours (range, 0.68 to 2.01; interquartile range, 0.85 to 1.14) in the patients with P. vivax malaria and 0.90 hours (range, 0.68 to 1.64; interquartile range, 0.78 to 1.07) in those with P. falciparum malaria. By comparison, only 19 of 5076 patients with P. falciparum malaria (<1%) who were treated with oral artesunate in Southeast Asia had a parasite clearance half-life of less than 1 hour. Adverse events were reported in 14 patients (67%), with nausea being the most common. The adverse events were generally mild and did not lead to any discontinuations of the drug. The mean terminal half-life for the elimination of KAE609 was 20.8 hours (range, 11.3 to 37.6), supporting a once-daily oral dosing regimen. CONCLUSIONS: KAE609, at dose of 30 mg daily for 3 days, cleared parasitemia rapidly in adults with uncomplicated P. vivax or P. falciparum malaria. (Funded by Novartis and others; ClinicalTrials.gov number, NCT01524341.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Self-citation
Cited by
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Phillips, M. A., Lotharius, J., Marsh, K., White, J., Dayan, A., White, K. L., Njoroge, J. W., El Mazouni, F., Lao, Y., Kokkonda, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa6645 · Cited by 371
White, N. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-1731-1 · Cited by 230
Self-citationQiu, D., Pei, J. V., Rosling, J. E. O., Thathy, V., Li, D., Xue, Y., Tanner, J. D., Penington, J. S., Aw, Y. T. V., Aw, J. Y. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33403-9 · Cited by 70
Metadata
- Authors
- White, N. J., Pukrittayakamee, S., Phyo, A. P., Rueangweerayut, R., Nosten, F., Jittamala, P., Jeeyapant, A., Jain, J. P., Lefèvre, G., Li, R., Magnusson, B., Diagana, T. T., & Leong, F. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-31
- Volume
- 371
- Issue
- 5
- Pages
- 403-410
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2143048218
- Cited by
- 240
- References
- 1
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spiroindolone KAE609 for Falciparum and Vivax Malaria. https://app.cochat.ai/papers/10.1056/nejmoa1315860
- The paper
- White, N. J., Pukrittayakamee, S., Phyo, A. P., Rueangweerayut, R., Nosten, F., Jittamala, P., Jeeyapant, A., Jain, J. P., Lefèvre, G., Li, R., Magnusson, B., Diagana, T. T., & Leong, F. J. (2014). Spiroindolone KAE609 for Falciparum and Vivax Malaria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1315860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.